CINCINNATI, OH--(Marketwire - December 11, 2008) - Medpace, Inc. today announced the addition of Dr. Bernard E. Ilson MD, FACP, as Medical Director building on their therapeutic focus in nephrology and broadening strength in clinical pharmacology. Dr. Ilson has over 21 years of experience in clinical drug development with GlaxoSmithKline Pharmaceuticals and Cardiokine. Dr. Ilson brings an extensive drug development experience to Medpace, spanning Phases I-IV. During his tenure with GSK, Dr. Ilson carried several drugs through from early phase development to regulatory approval and product launch, including Teveten and Coreg. Dr. Ilson had been head of the Cardiovascular and Metabolic Therapy areas within Clinical Pharmacology, Full Development with responsibility for late phase development of several novel drug products, in licensing and product line extensions. He was responsible for the design and conduct of Levitra and Vesicare thorough QT studies, resulting in regulatory approval of both drugs, and he took a leading role in establishing GSK’s strategy in the clinical evaluation of arrhythmia risk of new chemical entities. More recently, Dr. Ilson served as Chief Medical Officer of Cardiokine, a specialty pharmaceutical company focused on the development of pharmaceuticals for the treatment and prevention of heart failure and related cardiovascular indications.
